BISOLVON ® Bromexina

BISOLVON ® is a drug based on Bromexina

THERAPEUTIC GROUP: Mucolytics

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications BISOLVON ® Bromexina

BISOLVON® is indicated for the symptomatic treatment of respiratory diseases characterized by hypersecretion of thick and viscous mucus.

Mechanism of action BISOLVON ® Bromexina

BISOLVON ® is a medicinal product based on Bromexina, a synthetic active ingredient obtained from plant extracts such as vasicin, with a marked mucolytic activity.

The increase in the volume and frequency of expectoration, useful in significantly reducing the pain associated with cough, is determined by the ability of Bromexina to thin the mucus deposits, increasing the secretion of neutral mucins and hydrolyzing the acid mucopolysaccharides.

The aforementioned biochemical modifications induce a secretolytic and secretomotor effect, increasing the mucociliary clearance and thus facilitating the passage of these secretions through the respiratory tree.

After its therapeutic action, after an intense gastro-intestinal absorption and a distribution mainly concentrated at the pulmonary level, Bromexine, mainly in the form of glucoronides, is eliminated by more than 90% through the urine.

Studies carried out and clinical efficacy

PHARMACEUTICALS OF BROMEXIN

Drug Dev Ind Pharm. 2012 Nov; 38 (11): 1319-27. Epub 2012 Jan 28.

An innovative pharmacokinetic work that demonstrates how the association between amino acids and Bromexine could be more advantageous from the kinetic point of view, significantly improving the therapeutic profile of the same active ingredient.

PHARMACOLOGICAL INTERACTIONS

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007 Oct; 32 (5): 855-61.

Pharmacokinetic study that seeks to characterize the possible drug interactions present between Bromexina and other active ingredients such as cefaclor, demonstrating the absence of changes in the half-life rather than in the drug's excretion modalities.

BROMEXINE AND CHRONIC PANCREATITIS FROM ALCOHOL

Alcohol Clin Exp Res. 2005 Dec; 29 (12 Suppl): 272S-6S.

Interesting study that demonstrates how the administration of Bromexina can be effective in improving the clinical and biological course of chronic pancreatitis in alcoholic patients, improving the fluidity of pancreatic juice and avoiding the formation of protein aggregates.

Method of use and dosage

BISOLVON ®

Bromexina hydrochloride 8 mg tablets;

Powder for oral solution of 2 mg of Bromexina Hydrochloride per ml of solution;

4 mg syrup of Bromexina Hydrochloride per ml of solution.

The daily dosage of Bromexina should be defined by your doctor based on the overall picture of the patient's health and the severity of his / her clinical picture.

Generally in adults the daily dose of 8 mg is sufficient to guarantee a significant improvement in the clinical condition.

Warnings BISOLVON ® Bromexina

Although the use of BISOLVON ® is generally well tolerated and has no clinically relevant side effects, it would be advisable to consult your doctor before taking it.

The increase in volume and frequency of expectoration, in the presence of respiratory difficulties such as those commonly found in the elderly or in children, could cause a stagnation of the mucous component causing both broncho-obstruction and at the same time also facilitating the overlap of bacterial infections.

BISOLVON ® syrup contains liquid maltitol, thus having a modest laxative effect.

PREGNANCY AND BREASTFEEDING

The absence of studies able to characterize the safety profile of Bromexina for fetal health and the ability of the same active principle to effectively cross the mammary filter concentrating in significant quantities in breast milk, extends the aforementioned contraindications to the use of BISOLVON ® also during pregnancy and subsequent breastfeeding period.

Interactions

Pharmacological interactions worthy of clinical relevance are currently unknown.

Contraindications BISOLVON ® Bromexina

The use of BISOLVON ® is contraindicated in patients hypersensitive to the active substance or to one of its excipients, in patients with gastro-duodenal ulcer and in patients under the age of 2 years.

Undesirable effects - Side effects

The use of BISOLVON ® could cause the onset of nausea, vomiting, diarrhea, abdominal pain and rarely neurological symptoms or hypersensitivity reactions to the active ingredient.